Federal Signal Climbs on Q1 Figures
Federal Signal Corporation (NYSE: FSS) shares gained ground Wednesday, The Downers Grove, Ill.-based company, claiming to be a leader in environmental and safety solutions, reported financial results for the first quarter ended March 31, 2025.Consolidated net sales for the first quarter were $464 million, an increase of $39 million, or 9%, compared to the prior-year quarter. Net income for the first quarter was $46.3 million, or $0.75 per diluted share, compared to $51.6 million, or $0.84 per diluted share, in the prior-year quarter.The Company also reported adjusted net income for the first quarter of $47.0 million, or $0.76 per diluted share, compared to $39.5 million, or $0.64 per diluted share, in the prior-year quarter. The Company is reporting adjusted results to facilitate comparisons of underlying performance on a year-over-year basis.With our teams' continued focus on operational execution and serving our customers, our businesses were able to deliver 9% year-over-year net sales growth, double-digit operating income improvement, gross margin expansion, and a 170-basis point increase in adjusted EBITDA margin during the first quarter," commented CEO Jennifer L. Sherman. "Our Environmental Solutions Group delivered 9% year-over-year net sales growth and a 17% increase in adjusted EBITDA.”FSS shares acquired $3.22, or 4.3%, to $78.81.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


